NMR culture anlaysis complies with ICH Q2A and B, says Spinnovation

- Last updated on GMT

NMR culture anlaysis fits ICH Q2A and B, says Spinnovation
CRO Spinnovation Biologics says its cell culture optimization technique complies with analytical methods detailed in ICH Q2A and Q2B guidelines.

The method – Spedia-NMR – uses nuclear magnetic resonance spectroscopy (NMR) to analyse bioproduction medias and identify process-critical analytes that can be used to manage culture consistency.

The Netherlands-based CRO said its in-house team have validated that the technique fits with the ICH guidelines, which cover testing and analytical methods used during bioproduction​.

CEO Frederic Girard said: “Over the past two years, our Spedia-NMR analysis method has demonstrated clear advantages for optimizing and trouble-shooting cell-based production systems, such as those used for the production of antibodies, cell therapeutics or vaccines.

This new step reached with the validation of our proprietary method further establishes that Spedia-NMR can be used with confidence not only by researchers, but also by upstream processing and quality assurance teams developing or investigating their process, either in a pilot or bio-manufacturing stage.”

Previously released data suggest that Spedia-NMR - which is central to the Spedia-Predict analysis service the CRO launched in April​ - method can monitor more than 50 analytes simultaneously and that the firm can process around 100 samples per day, with typical limits of detection and quantification being in the 1 – 10µM and 50-100µM range, respectively.

Culture analysis

The approach is one of a number of new culture analysis methods to have emerged this year as a result of the pharmaceutical industry's need to improve the quality of bioproduction processes.

Earlier this month for example Merck Millipore​ partnered with microRNA detection firm Sistemic to develop QC kits for stem cell production.

The idea is to develop a monitoring methodology utilizing Sistemic's microRNA marker detection system that can be used to improve the growth of cell culture produced using Merck’s CellReady platform.

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more